@article{75885e2191f247b19fcaf9e867e6488c,
title = "Effects of Mental Illness Exposure From Parents and Friends on Adolescent Mental Health and Well-Being",
abstract = "Youth exposure to mental illness in family or friends is a known risk fac-tor of internalizing disorders. The current study examines the relationship between mental illness exposure and adolescents{\textquoteright} mental health and well-being in a cross-sectional school-based population using all self-report measures. Multilevel modelling was used to estimate adjusted effect of mental illness exposure on mental health outcomes such as depression, anxiety, well-being, and quality of life. The results indicated that there are statistically significant associations between mental illness exposure (through parents only, friends only, both, or none) and adolescent mental health. Compared to adolescents who had no exposure, depression and anxiety were significantly higher for those who had exposure through parents only, friends only, or both. They also had significantly lower well-being and quality of life. This study provides insight into how exposure to mental illness through friends or parents re-lates to adolescents{\textquoteright} mental health.",
author = "Anderson, {Jacqueline R.} and Karabi Nandy and Fuller, {Anne K.} and Taryn Mayes and Stevie Spinelli and Suzanne Brann and Felicia Padilla and Jennifer Hughes and Trivedi, {Madhukar H}",
note = "Funding Information: Support: The YAM program was funded in part by the Rees-Jones Foundation, National Institute of Health, the W.W. Caruth Jr. Foundation, and the Hersh Foundation. This work was funded in part by the Center for Depression Research and Clinical Care, University of Texas Southwestern Medical Center, Dallas, Texas (PI: MHT). The content is solely the responsibility of the authors and does not necessarily represent the official views of the various funding organizations. Funding Information: The YAM program was funded in part by the Rees-Jones Foundation, National Institute of Health, the W.W. Caruth Jr. Foundation, and the Hersh Foundation. This work was funded in part by the Center for Depression Research and Clinical Care, University of Texas Southwestern Medical Center, Dallas, Texas (PI: MHT). The content is solely the responsibility of the authors and does not necessarily represent the official views of the various funding organizations. Funding Information: Disclosures: JRA, KN, AKF, TLM, SS, SB and MHT have received grant funding from the Rees Jones Foundation. SB has received grant funding from the University of Texas Southwestern Medical Center. JLH has received grants from the National Institute of Mental Health and Texas Health Resources Community, royalties from Guilford Press, consulting fees from Restoration Counseling, RTI International, and the JED Foundation, and payment from Nationwide Children{\textquoteright}s Hospital, the Association for Behavioral and Cognitive Therapies, and the Arkansas chapter of the American Foundation for Suicide Prevention, and has served on advisory boards for the Data and Safety Monitoring Board and as a board member for the American Psychological Association. MHT has received editorial compensation from Oxford University Press, and has served as a consultant or advisor for Acadia Pharmaceuticals Inc., Akili Interactive, Alkermes Inc., Allergan Sales LLC, Alto Neuroscience, Inc., Applied Clinical Intelligence, LLC, Axsome Therapeutics, Boehringer Ingelheim, Engage Health Media, GH Research, GreenLight VitalSign6, Inc., Heading Health, Inc., Health Care Global Village, Janssen – Cilag.SA, Janssen Research and Development, LLC (Advisory Committee Esketamine), Janssen Research and Development, LLC (panel for study design for major depressive disorder [MDD] relapse), Janssen - ORBIT, Legion Health, Jazz Pharmaceuticals, Lundbeck Research USA, Medscape, LLC, Merck Sharp & Dohme Corp., Mind Medicine (MindMed) Inc., Myriad Neuroscience, Neurocrine Biosciences Inc, Navitor Pharmaceuticals, Inc., Noema Pharma AG, Orexo US Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. (PsychU.org, MDD Section Advisor), Otsuka America Pharmaceutical, Inc. (MDD expert), Pax Neuroscience, Perception Neuroscience Holdings, Inc., Pharmerit International, LP, Policy Analysis Inc., Rexahn Pharmaceuticals, Inc., Sage Therapeutics, Signant Health, SK Life Science, Inc., Takeda Development Center Americas, Inc., The Baldwin Group, Inc., and Titan Pharmaceuticals, Inc. Publisher Copyright: {\textcopyright} SLACK Incorporated.",
year = "2023",
doi = "10.3928/00485713-20230324-01",
language = "English (US)",
volume = "53",
pages = "228--235",
journal = "Psychiatric Annals",
issn = "0048-5713",
publisher = "Slack Incorporated",
number = "5",
}